



Thiazolidinediones used as a Potent Anticancer Agent

Shaivi Abu Saleh Nizam Uddin Siddik^{1*}, Sadiqul Alam¹, Ranadeep Borgohain², Monami Rajiung³

¹Department of Pharmacy, Tripura University (A Central University), Tripura, India

²Department of Pharmacy, Girijananda Chowdhury Institute of Pharmaceutical Science (GIPS), Assam, India

³Department of Pharmacy, NEF College of Pharmaceutical Education and Research, Assam, India

*Corresponding author email: asnuss.831@gmail.com

Received on: 30-07-2021; Revised on: 13-08-2021; Accepted on: 20-08-2021

ABSTRACT

Heterocyclic compounds and their derivative has been a fascinating field in medicinal chemistry because of their biological and pharmacological properties. Heterocyclic compounds are cyclic compounds in which the ring contains carbon, one or more atoms of other elements, commonly called as hetero atoms. Heterocyclic compounds usually contain hetero atoms like nitrogen, sulphur and oxygen. This study reflects the contribution of Thiazolidinedione as a scaffold to develop novel class of anticancer agents through PPAR- γ activation mechanism.

Keywords: Anticancer activity, Cancer, PPAR- γ , Thiazolidinedione.

DESCRIPTION

Cancer is nothing but unwanted growth of cells with a large impact on the people's health all over the world, making it the second leading cause of death after cardiovascular diseases [1]. According to the World Cancer Report 2014, cancer affected about 8.2 million lives in the year 2012 [2], and is believed to be the primary cause of death in the coming years.

Lung, breast, liver, stomach and bowel cancer are the most common cancer leading to deaths worldwide, accounting for nearly a half of all cancer deaths. The five most common types of disease diagnosed in 2012 were lung, prostate, colorectal, stomach and liver cancer among men [2]. Among the various types of malignant tumors reported so far breast cancer is the second most prominent reason for deaths among the women followed by lung, cervix and stomach cancer [3]. Colorectal cancer is the third leading cause of death in United States with 50% patients lost their lives in the year 2010 [2].

In search of potential anticancer agents, enormous efforts aimed at the implementation of new treatment strategies resulting in the development of scaffolds containing heterocyclic structure as their key structural design. Heterocyclic compound play an important role

in cancer therapy. Among them research scholars interest pointed towards thiazolidinedione, a structures that are able to provide high-affinity ligands for more than one type of receptor in modern medicinal chemistry, considering its broad spectrum of biological activities and affinity towards various biological targets [4]. Thiazolidinedione (TZDs), also called glitizines is a five-membered carbon ring molecules containing two heteroatoms (nitrogen and sulfur). One carbonyl group in the thiazide at position 4 and another at position 2 makes the heterocyclic compound a thiazolidine-2,4-dione[5] (Figure 1).




Figure 1: Thiazolidine -2, 4-dione.

The biological activities exhibited by TZD includes anti-hyperglycemic [6], antimicrobial [7], antiviral[8], antioxidant[9], anticancer [10], anti-inflammatory [11], anti-plasmodia, alpha glycosidase inhibitory, xanthine oxidase inhibitory activity etc. because of wide profile, thiazolidinediones are still in research for better, safer and potential pharmacological agents.

TZDs are one of the main heterocyclic ring systems having therapeutic importance when combined with other heterocyclic rings. For the investigation of novel and highly active therapeutic compounds the combination of two pharmacophores into a single molecule is an interesting, effective and mostly used direction in modern medicinal chemistry.

There are several mechanisms of anticancer activity of TZDs including

- Induction of apoptosis
- Cell differentiation
- Cell cycle arrest

Some of the TZDs are designed for the treatment of human cancers expressing high levels of Peroxisome Proliferator-activated receptor gamma (PPAR- γ), which is expressed in many human tumors including lung, breast, colon, prostate and bladder cancer. It is assumed that activation of PPAR- γ mediates their anticancer activity TZD ring has been used as a scaffold to develop this novel class of anticancer agents, encouraged by the literature report that toxicity of troglitazone is not due to TZD ring [12]. TZD moiety is directly connected to an N-heterocyclic ring so as to lower their toxic effects [13,14]. PPAR- γ , Peroxisome Proliferator-activated receptor gamma, also known as the glitazone receptor, or NR1C3 is a type II nuclear receptor that in humans is encoded by PPARG gene. PPAR- γ is the master regulator of adiposeness and the pharmacological target of the TZD class of insulin sensitizers. As metabolic regulators PPARs control the expression of genes involved in adipocyte differentiation, lipid and glucose metabolism, and as well as inflammation in immune cells and cell proliferation. Apart from the known metabolic actions, PPAR- γ has also been shown to be over expressed in. Numerous human cancers including breast, bladder, prostate, colon and thyroid. PPAR- γ agonist exhibit antitumor activities. It was also proposed to induce apoptosis in some malignant cell lineages. *In-vivo* and *in-vitro* studies have revealed ant proliferative and proapoptotic actions of PPAR- γ agonists indicating that PPAR- γ could be a promising therapeutic target for the treatment of cancers [15].

Antitumor activity of thiazolidinediones

Thiazolidinedione's (TZDs), like troglitazone, rosiglitazone, pioglitazone, and ciglitazone are some of the high-affinity ligands for PPAR- γ and are clinically being used as oral hypoglycemic agents in type 2 diabetes mellitus patients. TZDs activate the PPAR- γ causing transcriptional activation of insulin-sensitive genes in glucose homeostasis in a way which imitates the genomic effects of insulin. In addition, TZDs have been found to decrease colorectal, lung and breast. Cancer risks in diabetic patients. TZDs mediate their antitumor activities through the induction of cell cycle arrest, apoptosis, and re-differentiation. But the exact ant proliferative mechanisms of TZDs remain unclear; various evidences show that TZDs have both PPAR- γ dependent and independent mechanisms. PPAR- γ dependent mechanisms include the induction of pro-apoptotic proteins, phosphatase and tensing homolog (PTEN), p53, and BAD; and reducing the level of the anti-apoptotic proteins Bcl-2, Bcl-xL, and surviving, followed by the down-regulation of ERK 1/2, which induce apoptosis *via* the mitochondrial pathway. The PPAR- γ independent action of TZDs, which targets multiple signaling pathways, is mediated through the energy restriction mimetic effect and the induction of starvation-associated cellular responses [16].

CONCLUSION

The thiazolidine-2, 4-dione derivatives showing anticancer activity are mainly derivatives modified in the position 5 of the thiazolidine-2, 4-dione derivatives. The fifth position of thiazolidine-2, 4-diones being relatively more reactive, hence most of the modification at this position exhibits a wide spectrum of pharmacological properties. TZD moiety is directly connected to an N-heterocyclic ring in order to improve its anticancer activity. Thus the dose required for anticancer activity of TZD would be significantly lower than that required to bring hypoglycemic activity.

REFERENCES

1. Ahmad S, Alam O, Naim M, Shaquiquzzaman M, Alam M, Iqbal M. *Europ J Med Chem.* 2018; 157(3): 527-561.
2. Trotsko N, Przekora A, Zalewska J, Ginalska G, Paneth A, Wujec, M. *J Enzyme Inhibition Med Chem.* 2017; 33(1): 17-24.
3. Cancer Facts and Statistics. *American Cancer Society.* 2020.
4. Sharma P, Reddy ST, Thummuri D, Senwar K, Kumar PN, Naidu V, et al. *Euro J Med Chem.* 2016; 124: 608-621.
5. Fröhlich E, Wahl R. *Bio Med Res Int.* 2015; 57: 1-14.
6. Vasincu IM, Apotrosoaei M, Panzariu AT. *Molecules.* 2014; 19: 15005-15025.
7. Chadha N, Bahia MS, Kaur M, Silakari O. *Bio Med Chem.* 2015; 23: 2953-2974.

8. Sharghia H, Khalifeha R, Moeinia BF, Beyzava MH, Benic SA, Doroodmand MM. *J Iranian Chem Soci.* 2011; 8: 89-103.
9. Kumar A, Kumar S. *Pharma Sci.* 2016; 5(3): 8-34.
10. Panzariu AT, Aprotosoaei M, Profire L. *Chem Central J.* 2016;10: 6-10.
11. Singh T, Khobragade D. *JPSBR.* 2014; 4: 110-113.
12. Patil V, Tilekar K, Mehendale-Munj S, Mohan R, Ramaa C. *Euro J Med Chem.* 2010; 45(10): 4539-4544.
13. Corigliano D, Syed R, Messineo S, Lupia A, Patel R, Reddy C, et al. *Peer J.* 2018; 6: e5386.
14. Ayyakannu AN. *Int J Pharm Tech Res.* 2016; 9(3): 429-443.
15. Gurula H, Samuel S, Loganathan T. *Asian J Pharm Clin Res.* 2016; 9(4): 320-324.
16. Omar H, Salama S, Arafa E, Weng J. *Bio Chem.* 2013; 394(7): 865-870.